A Phase 2 trial to evaluate the activity of Imetelstat (GRN136L) in patients with essential thrombocythemia who require Cytoreduction and have failed or are intolerant to previous therapy, or who refuse standard therapy
ID Number 12-0420Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
You are being asked to participate in this research study because you have essential thrombocythemia (ET) or polycythemia vera (PV). The purpose of this study is to evaluate the safety and effectiveness of the experimental drug Imetelstat Sodium for Injection (also known as imetelstat and GRN163L). An experimental drug is one that has not been approved for general use by the U.S. Food and Drug Administration (FDA).
Recruiting Patients: No